Literature DB >> 30076375

Drug candidate and target for leishmaniasis.

Carolina M C Catta-Preta, Jeremy C Mottram.   

Abstract

Entities:  

Keywords:  Medical research; Microbiology

Mesh：

Substances：

Year:  2018        PMID： 30076375     DOI： 10.1038/d41586-018-05765-y

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Systematic in silico Evaluation of Leishmania spp. Proteomes for Drug Discovery.

Authors:  Crhisllane Rafaele Dos Santos Vasconcelos; Antonio Mauro Rezende
Journal:  Front Chem       Date:  2021-04-27       Impact factor: 5.221

2.  Phenotype Screening of an Azole-bisindole Chemical Library Identifies URB1483 as a New Antileishmanial Agent Devoid of Toxicity on Human Cells.

Authors:  Aurora Diotallevi; Laura Scalvini; Gloria Buffi; Yolanda Pérez-Pertejo; Mauro De Santi; Michele Verboni; Gianfranco Favi; Mauro Magnani; Alessio Lodola; Simone Lucarini; Luca Galluzzi
Journal:  ACS Omega       Date:  2021-12-15

3.  Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling.

Authors:  Exequiel O J Porta; Jaime A Isern; Karunakaran Kalesh; Patrick G Steel
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

Review 4.  A recent update on new synthetic chiral compounds with antileishmanial activity.

Authors:  Michele Verboni; Diego Olivieri; Simone Lucarini
Journal:  Chirality       Date:  2022-08-10       Impact factor: 2.183

5.  A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of Leishmania donovani.

Authors:  Emmanuel Broni; Samuel K Kwofie; Seth O Asiedu; Whelton A Miller; Michael D Wilson
Journal:  Biomolecules       Date:  2021-03-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.